DataMeds AI, Inc. has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission to disclose the execution of an ATM sales agreement and the filing of a legal opinion.
The report, dated November 17, 2026, confirms that on November 16, 2026, the company entered into an ATM sales agreement with Dawson James Securities, Inc. Under the terms of this agreement, DataMeds AI may offer and sell shares of its common stock, par value $0.0001 per share, from time to time through Dawson James Securities.
The offering is being conducted pursuant to a shelf registration statement on Form S-3 and an accompanying prospectus filed with the SEC on April 15, 2026, which was declared effective on May 7, 2026. The filing also references a prospectus supplement dated November 17, 2026.
As required by the filing, the legal opinion of Sheppard, Mullin, Richter & Hampton LLP regarding the legality of the shares that may be issued under the agreement is included as Exhibit 5.1. The report also includes the consent of the law firm, which is included within Exhibit 5.1.